{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-24-000153","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.853607+00:00","generated_at":"2026-05-30T00:35:09.917393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025","bullets":["Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.","Cash and cash equivalents $4.7M as of Sep 30, 2024.","Raised $13.9M gross proceeds since start of 2024, extending runway into mid Q1 2025.","Interim data from GRI-0621 Phase 2a biomarker study expected Q1 2025; topline Q2 2025.","Preclinical data presented; Japan patent granted; Australian study authorization received."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-24-000153","json":"https://secwatch.observer/filing/0001824293-24-000153.json","markdown":"https://secwatch.observer/filing/0001824293-24-000153.md","text":"https://secwatch.observer/filing/0001824293-24-000153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/0001824293-24-000153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/val-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:35:09.917393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}